Hisamitsu Pharmaceutical Co Stock Working Capital
| HTSUFDelisted Stock | USD 30.31 0.00 0.00% |
Hisamitsu Pharmaceutical Co fundamentals help investors to digest information that contributes to Hisamitsu Pharmaceutical's financial success or failures. It also enables traders to predict the movement of Hisamitsu Pink Sheet. The fundamental analysis module provides a way to measure Hisamitsu Pharmaceutical's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Hisamitsu Pharmaceutical pink sheet.
Hisamitsu |
Hisamitsu Pharmaceutical Co Company Working Capital Analysis
Hisamitsu Pharmaceutical's Working Capital is a measure of company efficiency and operating liquidity. The working capital is usually calculated by subtracting Current Liabilities from Current Assets. It is an important indicator of the firm ability to continue its normal operations without additional debt obligations. .
More About Working Capital | All Equity Analysis
Working Capital | = | Current Assets | - | Current Liabilities |
Current Hisamitsu Pharmaceutical Working Capital | 133.88 B |
Most of Hisamitsu Pharmaceutical's fundamental indicators, such as Working Capital, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Hisamitsu Pharmaceutical Co is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Working Capital can be positive or negative, depending on how much of current debt the company is carrying on its balance sheet. In general terms, companies that have a lot of working capital will experience more growth in the near future since they can expand and improve their operations using existing resources. On the other hand, companies with small or negative working capital may lack the funds necessary for growth or future operation. Working Capital also shows if the company has sufficient liquid resources to satisfy short-term liabilities and operational expenses.
CompetitionAccording to the company's disclosures, Hisamitsu Pharmaceutical Co has a Working Capital of 133.88 B. This is much higher than that of the Healthcare sector and significantly higher than that of the Drug Manufacturers—Specialty & Generic industry. The working capital for all United States stocks is significantly lower than that of the firm.
Hisamitsu Working Capital Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Hisamitsu Pharmaceutical's direct or indirect competition against its Working Capital to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Hisamitsu Pharmaceutical could also be used in its relative valuation, which is a method of valuing Hisamitsu Pharmaceutical by comparing valuation metrics of similar companies.Hisamitsu Pharmaceutical is currently under evaluation in working capital category among its peers.
Hisamitsu Fundamentals
| Return On Equity | 0.0504 | |||
| Return On Asset | 0.0212 | |||
| Profit Margin | 0.10 % | |||
| Operating Margin | 0.09 % | |||
| Current Valuation | 1.15 B | |||
| Shares Outstanding | 79.53 M | |||
| Shares Owned By Insiders | 26.45 % | |||
| Shares Owned By Institutions | 35.26 % | |||
| Price To Earning | 22.53 X | |||
| Price To Book | 0.97 X | |||
| Price To Sales | 0.02 X | |||
| Revenue | 120.19 B | |||
| Gross Profit | 70.07 B | |||
| EBITDA | 17.3 B | |||
| Net Income | 9.66 B | |||
| Cash And Equivalents | 151.32 B | |||
| Total Debt | 219 M | |||
| Debt To Equity | 0 % | |||
| Current Ratio | 4.46 X | |||
| Book Value Per Share | 3,393 X | |||
| Cash Flow From Operations | 19.2 B | |||
| Earnings Per Share | 1.06 X | |||
| Number Of Employees | 2.78 K | |||
| Beta | 0.51 | |||
| Market Capitalization | 2.45 B | |||
| Total Asset | 302.86 B | |||
| Retained Earnings | 216.56 B | |||
| Working Capital | 133.88 B | |||
| Current Asset | 171.81 B | |||
| Current Liabilities | 37.93 B | |||
| Z Score | 6.6 | |||
| Annual Yield | 0.02 % | |||
| Net Asset | 302.86 B | |||
| Last Dividend Paid | 42.0 |
About Hisamitsu Pharmaceutical Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Hisamitsu Pharmaceutical Co's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Hisamitsu Pharmaceutical using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Hisamitsu Pharmaceutical Co based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in employment. You can also try the Price Transformation module to use Price Transformation models to analyze the depth of different equity instruments across global markets.
Other Consideration for investing in Hisamitsu Pink Sheet
If you are still planning to invest in Hisamitsu Pharmaceutical check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Hisamitsu Pharmaceutical's history and understand the potential risks before investing.
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum |